He concluded that KRA
also failed to demonstrate that the direct procurement and the award of the tender to the firm satisfied the tests prescribed under the law.
Kenya is renowned for its entrepreneurial spirit and its technological and financial innovations and we are proud to support the KRA
as it demonstrates that e-government is an attainable reality.
Canal will shorten this route by some 1,200 kilometres and thereby significantly reduce transport costs for oil and other cargo as ships will be able to pass from the Indian Ocean into the Gulf of Thailand and back.
Steve Van Beek, a Thailand-based adventurer and author of numerous books about Asia's great rivers, recalls visiting the area during the 1970s, when Bang Kra
Jao wasn't even marked on maps of Bangkok.
reports that one of its 300w systems is already being used by a U.
also suggested that buyers submit a determination letter to the Internal Revenue Service to find out if their targets' filings have been processed properly.
The second possibility is that intratumoral heterogeneity affected the KRAS status determination.
For example, KRAS  (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) gene mutations, which are present in 40% of colorectal adenocarcinomas, are predictive markers of nonresponse to anti-epidermal growth factor receptor (anti-EGFR)  antibodies (4-6), and BRAF (protooncogene B-Raf, serine/threonine-protein kinase B-Raf) mutations have been shown to be associated with poor prognosis (7).
NASDAQ: MRTX) is reprioritizing its development programs to capitalise on encouraging data and development opportunities in its sitravatinib and KRAS programmes, the company said.
JUNIPER, a global Phase 3, interventional, open-label study was designed to evaluate the efficacy and safety of abemaciclib versus erlotinib in patients with stage IV NSCLC with a detectable KRAS mutation, who have progressed after platinum-based chemotherapy and who may have received one additional systemic therapy.
The RAS proto-oncogenes (ERAS, KRAS, and NRAS) encode HRAS, KRAS 4A, KRAS 4B, and NRAS, 4 distinct but closely related and highly homologous proteins.
KRAS mutations are thought to underlie the pathogenesis of up to 30% of human tumors.